The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current ...

Acromegaly is a serious endocrine disease associated with increased mortality and comorbidity. 1 The main therapeutic goal in patients with acromegaly is, therefore, to eliminate (progression of ...

Jeison Rodriguez Hernandez, a 28-year-old Venezuelan man with the world's largest feet, received custom-made shoes from a ...

For informational purposes only. Consult a medical professional for advice. Source: Focus Medica. A rare condition which results from excessive production of growth hormone by the pituitary gland ...

Are you searching for medications to treat 'Acromegaly'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Acromegaly. The page includes both ...

According to a recent report by Market.us, the Global Acromegaly Treatment Market size is expected to be worth around USD 3.4 Billion by 2033 from USD 1.6 Billion in 2023, growing at a CAGR of 7.7% ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ...

The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants. “Paltusotine continues to exceed ...

SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee ...

Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal ...